Biosimilars Reviews Could Be Extended Two Months In BsUFA II
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA hopes for first-cycle approvals by putting applications in a system like the 'Program' used for new drug reviews.
You may also be interested in...
What Goes Up … US FDA Expects 2016 NME Approval Total To Come Down
After a record-setting 2015 for new drug approvals, there were not enough applications with user fee goals in 2016 to reach that level again.
Complex ANDAs To Be Allowed Pre-Submission Product Meetings
FDA will be able to give scientific advice and sponsors can familiarize reviewers with upcoming generic applications for complex products under new provision in GDUFA II.
Complex ANDAs To Be Allowed Pre-Submission Product Meetings
FDA will be able to give scientific advice and sponsors can familiarize reviewers with upcoming generic applications for complex products under new provision in GDUFA II.